In this review, the authors describe recent advances in disease classification, identification of prognostic factors, understanding of the genomic landscape, current treatment, and new therapies under investigation in acute myeloid leukemia (AML) in adults. The authors note that AML is cured in 35 to 40% of adult patients who are 60 years or younger and in 5 to 15% of patients who are older than 60 years. The reviewers describe the molecular heterogeneity of AML and its prognostic importance, which they note is just in the beginning stages of being translated into improved therapy.
Review: Acute Myeloid Leukemia
Oct 2015